Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia

Bowden, Nikola A.; Weidenhofer, Judith; Scott, Rodney J.; Schall, Ulrich; Todd, Juanita; Michie, Patricia T.; Tooney, Paul A.

doi:10.1016/j.schres.2005.11.012

Cited by 108 publications

(77 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In psychiatry, such studies have involved the use of whole blood [129131] , lymphocytes [132] or PBMC samples [133135] to identify potential biomarkers for Sz. Other studies examined proteomics information in RBC [109] , T cells [136] , and serum [61,109,137,138] in attempts to answer the same question.…”

Section: The Human Transcriptome and Human Proteome Studiesmentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

Identifying biomarkers that can be used as diagnostics or predictors of treatment response (theranostics) in people with schizophrenia (Sz) will be an important step towards being able to provide personalized treatment. Findings from the studies in brain tissue have not yet been translated into biomarkers that are practical in clinical use because brain biopsies are not acceptable and neuroimaging techniques are expensive and the results are inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for Sz as a valid alternative. Although there are some encouraging preliminary data to support the notion of peripheral biomarkers for Sz, it must be acknowledged that Sz is a complex and heterogeneous disorder which needs to be further dissected into subtype using biological based and clinical markers. The scope of this review is to critically examine published blood-based biomarker of Sz, focusing on possible uses for diagnosis, treatment response, or their relationship with schizophreniaassociated phenotype. We sorted the studies into six categories which include: (1) brain-derived neurotrophic factor; (2) inflammation and immune function; (3) neurochemistry; (4) oxidative stress response and metabolism; (5) epigenetics and microRNA; and (6) transcriptome and proteome studies. This review also summarized the molecules which have been conclusively reported as potential blood-based biomarkers for Sz in different blood cell types. Finally, we further discusses the pitfall of current blood-based studies and suggest that a prediction model-based, Sz specific, blood World Journal of Psychiatry W J P oriented study design as well as standardize blood collection conditions would be useful for Sz biomarker development.

show abstract

Section: The Human Transcriptome and Human Proteome Studiesmentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

show abstract

“…Peripheral mononuclear cells may reflect molecular processes in the CNS of schizophrenic patients and have been used to study various substances including cytokines (e.g., interleukins IL-6, IL-10, and IL-2), receptors for major neurotransmitters (e.g., dopamine, serotonin, and GABA A ), and G-protein subunits that regulate intracellular signal transduction. [53][54][55][56][57][58][59][60][61] Chertkow et al 62 used microarrays to examine the gene expression profile of peripheral mononuclear cells in schizophrenia patients on steady antipsychotic treatment before and 3 and 6 weeks after addition of fluvoxamine and found changes in transcripts related to Gprotein coupled receptors. Using customized cDNA array and real-time RT-PCR, they also found significant downregulation of chemokine receptors IL8RA and CCR1, and of RGS7 mRNA.…”

Section: Clinical Relevancementioning

confidence: 99%

Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?

et al. 2009

View full text Add to dashboard Cite

Summary: Many patients suffering from major psychiatric disorders do not respond adequately to monotherapy and require additional drugs. To date, there are no objective guidelines for deciding which combination may be effective, and the choice is based on previous clinical experience and on trial and error. Even when combination drugs are effective, the biochemical mechanisms responsible for the value-added effect are unknown. Understanding the mechanism of such synergism may provide a rational basis for choosing drug combinations and for developing more effective drugs. In schizophrenia, negative symptoms respond poorly to antipsychotics, but may improve when these are augmented with selective serotonin reuptake inhibitors (SSRI). This augmenting effect cannot be explained by summating the pharmacological effects of the individual drugs. We proposed that the study of SSRI augmentation can serve as a window to understanding the biochemical mechanisms of clinically effective drug synergism. In a series of studies we identified unique biochemical effects of the combination, different from each individual drug, and proposed that some of these are involved in mediating the clinical effect. Here we review some of the findings and propose that the mechanism of action involves regionally selective modulation of the GABA system. The evidence indicates that the SSRI antidepressant-antipsychotic combination may be a useful paradigm for studying therapeutically effective synergistic drug interactions in schizophrenia. Although as yet limited in scope, the findings of definable molecular targets for synergistic SSRIantipsychotic interaction provide new directions to inform future research and provide novel bio-molecular targets for drug development.

show abstract

“…Disease classification has already been performed as an important approach in the molecular diagnosis and classification of several illnesses, including schizophrenia Bowden et al, 2006;Kuzman et al, 2009;Woelk et al, 2011). We suggest that peripheral blood mRNA profiling is a feasible way to discriminate patients from controls, regardless of antipsychotic treatment.…”

Section: Discussionmentioning

confidence: 98%

Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls

Maschietto

Silva

Puga

et al. 2012

Psychiatry Research

View full text Add to dashboard Cite

Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia

Cited by 108 publications

References 28 publications

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?

Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls

Contact Info

Product

Resources

About